XIAO Zhiyan
Principal Investigator
Dr. Xiao Zhiyan received her Ph.D. in medicinal chemistry from the University of North Carolina at Chapel Hill in 2003. Following a brief post-doctoral period, she joined the Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences in 2004, where she is currently Professor of Medicinal Chemistry. Dr. Xiao's research emphasizes the integration of chemoinformatic techniques and medicinal chemistry efforts. Her research interests focus on rational drug design-guided lead identification and optimization, which involves two alternative approaches either oriented by molecular targets or guided by natural lead structures. Recently, her research efforts are mainly devoted to the discovery of drug candidates for metabolic diseases and malignant tumors.
1. Identification of 3, 4-disubstituted pyridine derivatives as novel CDK8 inhibitors. Eur. J. Med. Chem. 2021, 223: 113634.
2. Design, synthesis and biological evaluation of triaryl compounds as novel 20S proteasome inhibitors. Bioorg. Med. Chem. Lett. 2020, 30 (21): 127508.
3. Identification of xanthine oxidase inhibitors through hierarchical virtual screening. RSC Adv. , 2020, 10: 27752.
4. Identification of natural products as selective PTP1B inhibitors via virtual screening. Bioorg. Chem. 2020, 98: 103706.
5. Carboxylic acid promoted single-step indole construction from simple anilines and ketones via aerobic cross-dehydrogenative coupling. J. Org. Chem. 2018, 83 (23): 14472-14488.
6. Novel benzamido derivatives as PTP1B inhibitors with anti-hyperglycemic and lipid-lowering efficacy. Acta Pharm. Sin. B. 2018, 8 (6): 919–932.
7. Discovery of novel CDK inhibitors via scaffold hopping from CAN508. Bioorg. Med. Chem. Lett. 2018, 28 (8): 1386–1391.
8. SAR study on N 2, N 4-disubstituted pyrimidine-2,4-diamines as effective CDK2/CDK9 inhibitors and antiproliferative agents. RSC Adv. 2018, 8 (22): 11871–11885.
9. Design, synthesis and biological evaluation of novel indolin-2-ones as potent anticancer compounds. Bioorg. Med. Chem. Lett. 2017, 27 (15): 3326-3331.
10. Strategies for the optimization of natural leads to anticancer drugs or drug candidates. Med. Res. Rev. 2016, 36 (1): 32-91.
